1282516-69-1

Basic information

• Product Name: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-
• Synonyms: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-;9-Bromo-5,6-dihydro-2-iodo-imidazo[1,2-d][1,4]benzoxazepine;9-Bromo-2-iodo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine
• CAS NO: 1282516-69-1
• Molecular Formula: C₁₁H₈BrIN₂O
• Molecular Weight: 391.00249
• Mol File: 1282516-69-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 491.2±55.0 °C(Predicted)
• Appearance: /
• Density: 2.21±0.1 g/cm3(Predicted)
• PKA: 3.32±0.20(Predicted)
• CAS DataBase Reference: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-(1282516-69-1)
• EPA Substance Registry System: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-(1282516-69-1)

Safety Data

• Hazardous Substances Data: 1282516-69-1(Hazardous Substances Data)

Usage

Description

IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodois a complex heterocyclic organic molecule characterized by a fused ring structure that includes an imidazole and benzoxazepine ring system. IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodois further distinguished by the presence of a bromine atom at the 9-position and an iodo group at the 2-position. Its unique structure and reactivity make it a promising candidate for applications in medicinal chemistry and drug development. Due to its potential reactivity and toxicity, it requires careful handling and storage.

Uses

Used in Medicinal Chemistry:
IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodois used as a precursor or intermediate in the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Drug Development:
IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodoserves as a tool in drug development, aiding researchers in understanding the interactions between molecules and their biological targets, which is crucial for the design of effective medications.
Used in Chemical Research:
IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodois utilized in chemical research to explore its reactivity and potential use in the formation of new chemical entities.
Used in Biological Research:
It may also be employed in biological research to study its interactions with biological systems, providing insights into its potential as a therapeutic agent or a probe for biological investigations.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodois used as a key component in the development of novel therapeutic agents, targeting specific medical conditions that require innovative treatment options.
Proper handling and storage are essential due to the compound's potential reactivity and toxicity, ensuring the safety of researchers and the integrity of experiments.

Upstream product

• 22532-62-3 4-bromosalicylaldehyde 

Downstream Products

• 1282516-74-8 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d]-[1,4]oxazepine-2-carboxylic acid 
• 1401303-65-8 8-bromo-2-pyridin-2-yl-4,5-dihydro-6-oxa-1,3a-diazabenzo[e]azulene 
• 1401300-81-9 2-(2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)benzenesulfonamide 
• 1282512-48-4 taselisib 
• 2060571-02-8 (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide 

Relevant articles and documents

INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

An inhibitor containing a tricyclic derivative, a preparation method therefor and a pharmaceutical composition comprising the inhibitor, as well as a use thereof as a phosphoinositide 3 kinase (PI3K) inhibitor in the treatment of cancer and diseases or conditions mediated by or dependent on PI3K imbalance.

Manufacture of the PI3K β-Sparing Inhibitor Taselisib. Part 1: Early-Stage Development Routes to the Bromobenzoxazepine Core

Two convergent regioselective routes for the synthesis of the tetracyclic imidazobenzoxazepine triazole 1, a key intermediate toward the synthesis of taselisib, are described. In the first-generation route, a chemoselective Negishi cross-coupling reaction was developed between iodoimidazole 3 and triazole 7, which enabled the delivery of initial kilogram quantities of 1. Because of the inefficiencies in the preparation of the imidazole 3, a second-generation route via a highly regioselective imidazole ring formation between α-chloroketone 11 and aryl amidine 12 was developed. The resulting imidazole 14 provided the handle to efficiently install the seven-membered benzoxazepine ring system in one pot with two-step N-alkylation and SNAr tandem reactions.

BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE

Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.